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In an effort to overcome the palatability issues currently constraining the effective delivery of 
praziquantel (PZQ) via feed to treat monogenean parasites in yellowtail kingfish, this study 
compared the bioavailability and palatability of PZQ in hydrogenated castor oil (HCO) solid 
lipid nanoparticles (SLN) against pure PZQ in this species.  Improving bioavailability would 
facilitate lower dietary inclusion levels to achieve the same therapeutic dose and therefore 
reduce the bitterness of feeds containing PZQ. Bioavailability was determined by co-
administering feed with either pure PZQ, HCO-SLN or HCO-SLN coated with chitosan via 
intubation and quantifying the pharmacokinetics response. In contrast to studies with 
mammals, the results demonstrated that PZQ in HCO-SLN had equal bioavailability to pure 
PZQ in yellowtail kingfish, including when HCO-SLN were coated with chitosan. We 
hypothesise that the lack of improvement in bioavailability may be due to the lack of M cells 
and Peyer’s patches in fish and the subsequent inability of fish to take nanoparticles directly 
into the lymphatic system. Furthermore, palatability of the feeds medicated with PZQ was not 
improved when the PZQ was incorporated into HCO-SLN, possibly due to the low loading 
rate of PZQ within the HCO-SLN and the subsequent thick coating of nanoparticles that was 
required on the surface of the feed pellets. Combined, these data demonstrate that the SLN 
used in the current study are not capable of delivering the benefits required to enable 
effective in-feed treatment of PZQ against monogenean parasites in yellowtail kingfish.  
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The culture of Seriola spp. is well established in Japan (Nakada, 2008) and an emerging 
industry in many other countries and regions including Australia, New Zealand, the Americas 
and Europe (Abbink et al., 2012; Benetti et al., 2005; Booth et al., 2010; Sarropoulou et al., 
2017; Symonds et al., 2014). In all regions where Seriola spp. are cultured in the sea, the 
management and treatment of monogenean parasites such as Benedenia seriolae, 
Neobenedenia spp. and Zeuxapta seriolae creates challenges and cost burdens to industry 
(Ernst et al., 2005; Hutson et al., 2007). Left untreated, these parasites can cause growth 
impairment and morbidity or mortality due to anaemia and secondary bacterial infections. 
The most commonly applied treatment against such parasites is to bathe the fish in hydrogen 
peroxide (Hirazawa et al., 2016); a process that is efficacious and environmentally safe, but 
which is labour intensive and potentially harmful to fish and farm staff if handled or 
administered incorrectly.  
Praziquantel (PZQ) is a broad spectrum anthelmintic drug (Watson, 2009), which is highly 
effective against monogenean parasites in finfish (Buchmann, 1987; Hirazawa et al., 2000; 
Hirazawa et al., 2004). Bathing in PZQ is efficacious (Kim and Cho, 2000), but carries many 
of the same challenges as bathing in hydrogen peroxide and with the added disadvantage of 
discharging PZQ into the environment. Whilst oral (in-feed) delivery of PZQ can be highly 
efficacious, its strong bitter taste remains a major constraint to effective oral delivery in 
Seriola spp. (Hirazawa et al., 2013; Partridge et al., 2016; Williams et al., 2007) and other 
freshwater and marine fish species (Forwood et al., 2013; Hirazawa et al., 2004). 
Prior research has demonstrated that microencapsulating PZQ can improve its palatability to 
yellowtail kingfish Seriola lalandi (Partridge et al., 2014), however these microcapsules 
reduced drug bioavailability. Solid lipid nanoparticles (SLN), on the other hand, have been 
demonstrated to increase the bioavailability of many hydrophobic drugs (including PZQ) in 
other animals (Xie et al., 2011; Xie et al., 2010; Yang et al., 2009). Solid lipid nanoparticles 
are colloidal particles (50 to 1000 nm) made from lipids (which are solid at room 
temperature) and emulsifiers. Whilst the exact mechanisms of improved bioavailability of 
drugs delivered in SLN remains largely unknown, they have been attributed to factors 
including adherence of the SLN to the mucosal wall, with the drug molecules being released 














surface active mono and diacylglycerols solubilizing the drug and (at least partial) direct 
uptake into the lymphatic system, thus reducing the pre-systemic drug metabolism in the liver 
(Muller and Keck, 2004). 
A number of studies have illustrated the positive impact of SLN on the oral bioavailability of 
PZQ in different animal models such as mice, rats and dogs (Xie et al., 2011; Xie et al., 2010; 
Yang et al., 2009), however to our knowledge they have never been used in fish. Increased 
bioavailability of PZQ in fish would facilitate lower dietary inclusion levels to achieve the 
same therapeutic dose, and therefore reduce the bitterness of feeds containing PZQ. 
Furthermore, SLN should directly mask bitterness, thereby delivering a two-pronged benefit. 
Solid lipid nanoparticles are therefore hypothesised to have the potential to deliver the 
outcomes required to facilitate the effective treatment of monogeneans via feed. 
This study assessed the suitability of SLN for delivering PZQ to yellowtail kingfish. 
Hydrogenated castor oil-based SLN (HCO-SLN) were selected based on published data 
demonstrating a 15-fold improvement in bioavailability when such nanoparticles containing 
PZQ were administered to mice (Xie et al., 2010). Four types of HCO-SLN were formulated 
and assessed for physical characteristics. In addition to standard HCO-SLN, surface coating 
the HCO-SLN with chitosan was investigated on the basis that it has been demonstrated to 
improve mucoadhesion and transmucosal drug permeation, which may also lead to improved 
drug absorption following oral administration (Luo et al., 2015). Following physical 
characterisation, bioavailability and palatability studies were performed using the two particle 
types deemed to have the greatest potential for inclusion into yellowtail kingfish diets.  
Methods 
Nanoparticle Preparation  
Solid lipid nanoparticles were prepared using a method similar to that described by Xie et al 
(2010). Praziquantel (0.2 g) was dissolved in 1.8 g of HCO in a boiling water bath with 
continuous stirring. Following this, 40 mL of a 1% PVA solution (preheated in a boiling 
water bath) was poured into this molten lipid phase under magnetic stirring, then sonicated 
for 5 minutes at an amplitude of 35% and homogenized to form a nanoemulsion. The hot 
nanoemulsion was quickly poured into 200 mL of cold water to obtain a nanoparticle 
suspension. The nanoparticles were collected by centrifugation at 12,000 rpm for 90 minutes 
at 4°C, and suspended in 30 mL of distilled water. The freshly prepared suspension was 














SLN particles (Table 1) were also prepared following the general method described above. 
Different variables (i.e. mass ratio between solid lipid and chitosan and different preparation 
techniques) were tested to optimize the formulation in order to obtain products with powder-
like appearance, small size and good redispersion properties.  
The particles prepared were assessed for parameters including size, polydispersive index 
(PDI), zeta potential, redispersing properties and drug loading rate. Dynamic light scattering 
analysis (DLSA; Malven Zetasizer Nano, Malvern, UK) was used to determine particle size, 
PDI and zeta potential. Particle size was determined within the nanoemulsion and in the 
redispersed lyophilized HCO-SLN particles. In order to measure the size of the redispersed 
nanoparticles, 10 mg of lyophilized particles were added to 10 mL of deionised water and 
shaken by hand until the disappearance of particles was visually evident. Loading rate was 
determined by extracting PZQ from a 10 mg sample of lyophilized powder with 10 mL 
dimethyl sulfoxide. The mixture was sonicated for 15 minutes prior to centrifugation at 
20,000 rpm for 15 minutes and the supernatant was diluted and analysed to determine the 
PZQ content using HPLC.  
Bioavailablity and palatability studies were performed on regular HCO-SLN particles and on 
HCO-SLNchi3. The latter particles were selected from the three chitosan particle types tested 
based on their physical properties.  
 
Bioavailability Testing 
Three in vivo bioavailability studies were conducted in which yellowtail kingfish were 
intubated with feed and either pure PZQ, HCO-SLN or HCO-SLNchi3 according to Table 2.  
The first trial compared the bioavailability of HCO-SLN against pure PZQ in large fish (4.1 
kg). Three replicate, microchipped fish were intubated following the method of Tubbs and 
Tingle (2006). Commercial feed pellets (Skretting, Nova ME 9 mm) were briefly blended 
with the PZQ treatments and a small quantity of distilled water (5 mL/kg) and the resulting 
powder intubated into the fish. All three fish from each treatment were returned to the same 
tank and blood was collected from each fish at 0.5, 1.5, 3, 4, 6, 12, 24 and 48 hours post 
intubation. 
In previous studies, PZQ has been adhered to feed pellets with gelatine (Partridge et al., 
2014). Based on the results obtained in the first bioavailability trial and in order to determine 














whereby the same two treatments of HCO-SLN and pure PZQ were coated onto feed pellets 
with gelatine. In this trial, smaller fish (302 ± 15 g) were each intubated with ~20 commercial 
feed pellets (Skretting, Nova FF 5 mm) coated with 7.9 g/kg of active PZQ to achieve a dose 
rate of ca. 50 mg/kg body weight. Ten replicate fish were utilised per treatment and each fish 
was recovered in its own 180 L tank in order to quantify regurgitation of intubated pellets. 
Both the pure PZQ and HCO-SLN were adhered to the feed pellets using a 20% w/v gelatine 
solution at the rate of 50 mL/kg according to Partridge et al. (2014). Due to the smaller size 
of the fish, blood was collected from each fish less frequently at 3, 6, 24 and 48 hours post 
intubation. The third trial followed the same methods as the second trial but compared the 
bioavailability of pure PZQ against HCO-SLNchi3. Fish in this trial averaged 473 ± 17 g. 
In all trials, blood was collected from the caudal vein of anasethetised fish (MS222; 
100 mg/L) using needles and syringes coated with lithium heparin. Heparinsed blood was 
immediately transferred into foetal lithium heparin tubes and stored on ice for ca. 1 hour prior 
to separation of plasma via centrifugation at 15,000 rpm for 3 minutes. Plasma was stored at 
-80ºC prior to analysis of PZQ via LCMS. Ice cooled acetonitrile in 0.1% formic acid 
(160 μL) was added to 40 μL of plasma then vortexed for 10 seconds before centrifuging at 
13300 rpm for 10 minutes. The supernatant was collected and 10 μL analysed on an 
ABSCIEX TripleTOF™ 5600 LC/MS/MS. 
The maximum plasma concentration (Cmax) and time to reach maximum plasma concentration 
(Tmax) were noted directly from the individual plasma drug concentration versus time 
profiles, and the area under the curve (AUC) was calculated using the linear trapezoidal 
method.  Pharmacokinetic parameters were compared between treatments using one-way 
ANOVA. A Bonferroni correction was applied to achieve an experiment-wide error rate of 
0.05. All data presented are mean ± standard error.  
Palatability Trials 
Two trials were conducted in which the palatability of diets containing 5 g/kg of pure PZQ 
were compared against diets containing the same active quantity of PZQ in HCO-SLN (trial 
1) and HCO-SLNchi3 (trial 2). Both pure PZQ and nanoparticles were adhered to commercial 
5 mm pellets (Skretting, Nova FF) with gelatine as described above. Two control treatments 
that did not contain PZQ were also included; one in which the pellets were coated with the 
same quantity of gelatine and the second an uncoated control. Each treatment was tested in 














tank availability). Each 180 L tank was stocked with 5 fish, with an average weight of 323 ± 
5 g (trial 1) and 332 ± 5 g (trial 2).  
Fish were acclimated to the trial tanks for 5 days during which time they were fed the 
uncoated control diet (5 mm Skretting, Nova FF). After switching to the treatment diets, the 
fish were offered 80% of a full ration based on their weight and water temperature from 
published Seriola feeding tables (Masumoto, 2002). This fixed ration was split into two equal 
portions offered at 8 am and 3 pm daily for 5 days and would have provided a PZQ dose of 
66 mg/kg/day in Trial 1 and 68 mg/kg/day in Trial 2 if 100% of the ration was consumed. 
The entire ration of the floating pellets was added to the tank at once and the fish given three 
minutes to consume the ration. For those tanks in which the entire ration was eaten, the time 
taken to do so was recorded. For those tanks in which the entire ration was not consumed, 
uneaten pellets were removed after three minutes, counted and converted to a weight based 
on their predetermined average weight.  
Data from the five day trial period was analysed by treatment as follows: 
1. The percentage of the total ration offered that was consumed.  
2. The percentage of the ten rations offered that were consumed within three 
minutes.  
3. Average time taken to consume a ration (only for those rations consumed within 
three minutes). 
 
These three parameters were compared between treatments using one-way ANOVA, with a 
Bonferroni correction applied to achieve an experiment-wide error rate of 0.05. Where a 
significant difference was detected, Tukey’s HSD test was used for pairwise comparison of 
treatments. All data presented are mean ± standard error. 
 
Results  














A summary of the key physical characteristics of each particle type are shown in Table 3  
The mean diameter of the HCO-SLN particles within the nanoemulsion was 507 ± 10 nm 
with a polydispersive index (PDI) of 0.57 ± 0.17. The redispersed HCO-SLN particles had a 
larger mean size of 877 ± 115 nm and a PDI of 0.72 ± 0.11. The loading level of these 
particles was 7.87 ± 0.84%. All chitosan coated particles had a similar loading level, however 
these particles had significantly larger redispersed particle sizes that were influenced by the 
preparation technique (Table 3). The negative surface charge (zeta potential) of the regular 
HCO-SLN particles (-12.2 ± 0.5 mV) was reversed to positive in all tested chitosan coated 
particles. Particle types HCO-SLNchi1 and HCO-SLNchi2 both had a sponge-like appearance 
and redispersed slowly, while HCO-SLNchi3 had the more preferred powder-like appearance, 
more rapid redispersal and a smaller particle size. It was on the basis of these characteristics 
that HCO-SLNchi3 was selected for bioavailability and palatability testing.  
Bioavailability 
Results of the first trial are presented in Figure 1 and corresponding pharmacokinetic 
parameters are shown in Table 4. There were no significant differences in any of the PK 
parameters assessed. These data therefore suggested no improvement in the bioavailability of 
the HCO-SLN nanoparticles compared with pure PZQ.  
The second bioavailability trial utilised a larger number of smaller fish maintained in 
individual tanks, enabling greater replication and quantification of regurgitation, however, 
none of the fish regurgitated any of the intubated pellets. Results of this trial are shown in 
Figure 2, with the corresponding pharmacokinetic parameters in Table 5. In this trial there 
were again no significant difference in any of the PK parameters between the pure PZQ and 
HCO-SLN, demonstrating no improvement in bioavailability from the nanoparticles. 
Results of the third bioavailability trial testing chitosan coated particles (HCO-SLNchi3) 
applied to the feed pellets with gelatine are shown in Figure 3 with the corresponding 
pharmacokinetic parameters in Table 6. Again, no pellets were regurgitated in this trial. There 
were no significant differences in PK parameters between the two treatments, demonstrating 
no improvement in bioavailability of the HCO-SLNchi3 particles compared with pure PZQ. 
Furthermore, the PK parameters obtained in the current trial with the HCO-SLNchi3 were very 















Palatability parameters of the diets containing pure PZQ, HCO-SLN and HCO-SLNchi3 and 
the various control diets in the two trials are shown in Table 7. In both trials, all control diets 
were completely consumed (100 ± 0%) and the average time to consume the two control diets 
did not differ within trial, demonstrating no impact of gelatine coating on diet palatability.  
In both trials, consumption of the diets containing HCO-SLN was poor and not significantly 
different to the diet containing pure PZQ. In the first trial, fish ate 41 ± 10% of the diet 
containing HCO-SLN and 56 ± 9% of the pure PZQ diet. In this trial, none of the ten HCO-
SLN rations were completely consumed within three minutes and the pure PZQ rations were 
completely consumed on only 13 ± 13% of occasions. The time taken to consume the pure 
PZQ ration on these occasions was 84 ± 12 seconds, significantly higher than the two control 
diets (both 15 ± 1 seconds). In the second trial, consumption of the HCO- SLNchi3 and pure 
PZQ diets was equal (34 ± 6% and 36 ± 4%, respectively). On the one occasion where the 
fish ate the entire HCO-SLNchi3 ration within three minutes, the time taken to do so was 170 
seconds and on the one occasion where the fish ate the entire pure PZQ ration, the time taken 
to do so was 28 seconds. 
Discussion  
This is the first published report on the bioavailability and palatability of SLN containing 
PZQ in fish. The results demonstrated no improvement to either bioavailability or palatability 
of PZQ when administered to yellowtail kingfish in HCO-SLN or chitosan coated HCO-SLN.  
The lack of improvement in bioavailability of these nanoparticles is in contrast to the 
improvements reported in other animals as summarised in Table 8. Xie et al. (2010), for 
example, demonstrated a 15-fold improvement in AUC0-∞ in mice administered orally with 
PZQ in HCO-SLN nanoparticles (without chitosan). Similarly, Xie et al. (2011) obtained a 6-
fold increase in AUC0-∞ when the same nanoparticles were administered subcutaneously to 
dogs. Yang et al. (2009) obtained a 4-fold improvement in AUC0-∞ when PZQ was 
administered orally to rats in SLN made with the solid lipid Compritol 888 ATO. In all of 
these cases the improvement in AUC0-∞ was derived from a longer retention of PZQ in the 
body, as indicated by the increased elimination half-life (T1/2).   
Whilst the PK values obtained in this study are very different to those obtained in these other 
animals, they do align closely with those obtained in yellowtail kingfish by Tubbs and Tingle 
(2006). These authors co-administered pure PZQ with food via intubation and they obtained 














the current study (T1/2 5.4 to 11.4 hours and Tmax 3.3 to 6.0 hours). The slightly higher AUC0-
24 values obtained in the current study can be attributed to the slightly higher dose rate (50 
mg/kg) compared with that used by Tubbs and Tingle (2006) (40 mg/kg). The fish used by 
Tubbs and Tingle (2006) were 1 to 2 kg, considerably smaller than the fish used in our first 
trial (4.1 kg) and water temperature between the two studies was similar; 18 to 19ºC in Tubbs 
and Tingle (2006) and 19.7ºC in our first trial. Based on data from Pirozzi and Booth (2009), 
the routine metabolic rate of the 4.1 kg yellowtail kingfish used in our first trial should be 
approximately 20% higher than those used by Tubbs and Tingle (2006) at 19ºC. It would 
therefore be expected that the larger fish used in the current study would metabolise the drug 
more slowly, however most PK parameters were very similar between the comparable 
treatments in the two studies. This is also despite the fish used in the first study being 
anaesthetised several times over six hours in order to draw blood. Whilst this procedure may 
have altered drug metabolism, the comparison between the pure PZQ and PZQ in HCO-SLN 
remains valid as fish in both treatments would have been impacted equally.  In our second 
and third bioavailability trials, smaller fish were intubated with PZQ adhered to the feed 
pellets with gelatine. The routine metabolic rate of these smaller fish is ca. 1.5 times higher 
than the 4.1 kg used in the first trial (Pirozzi and Booth, 2009). A faster metabolism of PZQ 
in the smaller fish would therefore be expected, however they had slightly higher AUC 
values than the larger fish in the first trial, suggesting a slower release of PZQ from the 
gelatine. It should be noted however that in general the PK values in all three of the trials in 
the current study are not dissimilar and within 2 SD of each other. Furthermore, no errors 
were provided around the PK values provided by Tubbs and Tingle (2006). More targeted 
trials investigating the effect of fish size and water temperature on the metabolism of PZQ 
from gelatine coated diets will be required to fully elucidate these relationships.  
Whilst the bioavailability of PZQ is significantly increased in mammals using nanoparticles, 
it is noteworthy that the baseline bioavailability of pure PZQ in all of these animals (rats, 
mice and dogs) is very low relative to yellowtail kingfish. For example, whilst the AUC0-∞ in 
mice increased by a factor of 15 with HCO-SLN, the baseline value for those mice intubated 
with pure PZQ was only 4 µg.h/mL, substantially lower than the values of at least 100 
µg.h/mL obtained for yellowtail kingfish both in this study and that of Tubbs and Tingle 
(2006). The low bioavailability of orally administered pure PZQ in mammals is due to its 
short half-life (ca. 1 to 4 hours; Table 8) compared with the half-life in yellowtail kingfish 














including differences in body temperature and metabolic rates, and blood volume and 
circulation time. The circulating blood volume of the closely related Japanese yellowtail 
(Seriola quinqueradiata), for example, has been measured at 46 mL/kg with a circulation 
time of 1.3 minutes (Brill et al., 1998). Yellowtail kingfish of two kilogram body mass have a 
cardiac output of ca. 30 and 60 mL/min at 20 and 25ºC, respectively (Clark and Seymour, 
2006). If they have a similar circulating blood volume to Japanese yellowtail then their 
circulation time is similar at 1.5 to 3 minutes across this temperature range. Mice, on the 
other hand, have a higher circulating volume of ca. 80 mL/kg but a much more rapid blood 
circulation time of just 15 seconds (Welsher et al., 2011). Given that praziquantel undergoes 
significant breakdown in the liver, this rapid circulation time is likely responsible for a much 
faster rate of hepatic metabolism and the subsequently low values of Cmax, Tmax, T1/2 and 
AUC0-∞ compared with those in yellowtail kingfish.  
The large improvement in bioavailability of PZQ in SLN in mammals compared to yellowtail 
kingfish therefore points to physiological differences in the mechanisms by which SLN are 
processed. The improved bioavailability of PZQ within HCO-SLN in mice was attributed to a 
number of possible factors leading to improved systemic circulation. One mechanism 
proposed by Xie et al. (2010) was bioadhesion and/or lodgement of the nanoparticles in the 
intervillar spaces in the gastrointestinal tract. However, these particles had a negative zeta 
potential, which suggests they should not be attracted to the mucosa to the same extent as the 
positively charged chitosan-coated HCO-SLN trialled in the current study, yet we obtained 
no improvement in PZQ bioavailability in these nanoparticles. This suggests that either this 
mechanism of bioadhesion is not at play in yellowtail kingfish, or that the larger size of the 
chitosan-coated particles offset any benefit to adherence to the gut mucosa. The mass ratio of 
chitosan to SLN used in the current study was within the range that has been reported in the 
literature (Luo et al., 2015), however, there appears to be no reports on the effect of size and 
redispersibility of lyophilized chitosan-SLN.  
The second mechanism reported by Xie et al. (2010) was SLN permeating the intestinal 
membrane, thereby allowing their direct uptake into the blood stream. The HCO-SLN 
particles in our study were larger than those of Xie et al. (2010) (877 vs 344 nm), suggesting 
that this may have limited or prevented their direct uptake. Kulkarni and Feng (2013) suggest 
that in mammals only particles <500 nm can be absorbed by enterocytes. If this is the case 
with fish, our redispersed particles may have been too large for this uptake mechanism. 














yellowtail kingfish can absorb such particles directly into the blood stream and whether the 
bioavailability of such smaller particles would be improved.  
The final mechanism proposed by Xie et al. (2010) for the improved bioavailability of HCO-
SLN in mice was due to enhanced lymphatic transport, as the uptake of nanoparticles into the 
lymphatic system (as opposed to the circulatory system) would significantly reduce the rapid 
hepatic metabolism of the drug. The main route of nanoparticle uptake into the mammalian 
lymphatic system is via the M cells of Peyer’s patches, which can absorb particles up to ca. 
5000 nm (Florence, 1997; Kulkarni and Feng, 2013). Fish, however, lack M cells and Peyer’s 
patches (Rombout et al., 2014) and this is therefore likely to be a major contributor to the 
lack of bioavailability improvement in the HCO-SLN in yellowtail kingfish. This is 
supported by Bargoni et al. (1998) who demonstrated that uptake of SLN into the lymph of 
rats is significantly greater than the uptake into blood. Whilst fish do not have M cells, they 
do have mucosal cells in the lower half of the intestine which resemble immature M cells and 
which have a demonstrated ability to endocytose antigens (Secombes and Ellis, 2012). 
Whilst there is some evidence that such cells can internalise such large particles (Gratton et 
al. 2008) however this must be tested in fish.  
The lack of improvement in palatability of the diets containing HCO-SLN was unexpected 
and we hypothesize that the low loading rate of PZQ within the nanoparticles may have 
contributed to this poor palatability. The low loading rate necessitated the application of 
50 grams of nanoparticles per kilogram of food to achieve a 5 g/kg dietary inclusion level of 
PZQ. As this quantity of nanoparticles had to be coated to the outer surface of the feed 
pellets, it resulted in a very thick coating of particles, which is likely to have impacted the 
taste and/or smell of the diets. A control diet coated with HCO-SLN nanoparticles without 
PZQ would have been effective at testing this hypothesis. Incorporation of the nanoparticles 
within the diet prior to extrusion may have been effective at reducing this problem, however 
the incorporation of 50 g/kg of nanoparticles is also likely to impact on the physical 
characteristics of the extruded pellet (for example water stability and buoyancy). 
Furthermore, given that the stability of the nanoparticles to the temperatures and pressures of 
the extrusion process are unknown and due to the difficulties of preparing small batches of 
extruded pellets, this avenue was not pursued.  
In conclusion, the incorporation of PZQ into hydrogenated castor oil, solid lipid nanoparticles 














nanoparticles were incorporated. Further studies testing smaller nanoparticles may be 
warranted to test the theories of direct uptake into the circulatory system by enterocytes or 
into the lymphatic system via those mucosal cells which resemble M cells. Whilst 
improvements to bioavailability would lead to lower dietary inclusion levels, the low loading 
rate of PZQ, which is characteristic of SLN, is likely to still provide challenges to dietary 
inclusion. 
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Table 1: Composition and preparation techniques of chitosan coated HCO-SLN nanoparticles. 
Component Role HCO-SLNChi1 HCO-SLNChi2 HCO-SLNChi3 
PZQ Active Ingredient 100 mg 100 mg 100 mg 
HCO Solid lipid 900 mg 900 mg 900 mg 
PVA Surfactant 1% w/v, 20 mL 1% w/v, 20 mL 1% w/v, 20 mL 
Chitosan Coating 200 mg 100 mg 100 mg 
Preparation technique   
HCO and PZQ  
emulsified in PVA 
solution, homogenized, 
and redispersed in 
100mL cold water. 
10mL chitosan (1%) 
then added to the 
mixture before freezing 
then lyophilizing. 
HCO and PZQ 
emulsified in  
premixed PVA and 
chitosan solution, 
homogenized and 
redispersed in 100 mL 




As per HCO-SLNChi2 
but the mixture was 
centrifuged at 18,000 

















Table 2: Treatments tested in bioavailability trials.  
          
Trial PZQ Type n Fish Size (g) Intubation Method 
1 
HCO-SLN 








10 473 ± 17 Gelatin coated pellets 
pure PZQ 
















Table 3: Particle characteristics (*no replicate value obtained) 
  HCO-SLN HCO-SLNchi1 HCO-SLNchi2 HCO-SLNchi3 
Nanoemulsion size (nm) 507 ± 10 nd nd nd 
Redispersed size (nm) 877 ± 115 10860 ± 468 7683 ± 474 4651 ± 635 
PDI 0.57 ± 0.17 nd nd nd 
Zeta potential -12.2 ± 0.5 nd +37.2 ± 2.1 +8.7 ± 0.7 
PZQ loading 7.87 ± 0.84% 6.56* 7.71 ± 2.89% 7.99 ± 0.61% 























Table 4: Comparison of mean pharmacokinetic parameters after oral administration of 
pure PZQ (control) or HCO-SLN (50 mg PZQ per kg) with powdered feed. No 
significant differences in any parameters between treatments (P > 0.05, with 
the Bonferroni).  
      
PK parameter 
Control HCO-SLN 
(n=3)  (n=3) 
Tmax (h) 5.0 ± 1.0 6.0 ± 0.0 
T1/2 (h) 7.2 ± 0.4 11.4 ± 4.4 
Cmax (µg/ml) 5.5 ± 1.5 5.8 ± 0.5 
AUC0-24h (µg·h/mL) 81 ± 14  105 ± 7 
AUC0-48h (µg·h/mL) 99 ± 33 143 ± 32 
AUC0-∞ (µg·h/mL) 100 ± 34 155 ± 42 
















Table 5: Comparison of mean pharmacokinetic parameters in 305 g yellowtail kingfish 
after oral administration of pure PZQ (control) or HCO-SLN (50 mg PZQ per 
kg) coated to feed pellets with gelatine. No significant differences in any 
parameters between treatments (P > 0.05, with the Bonferroni). 
      
PK parameter 
Control HCO-SLN 
(n = 10) (n = 10) 
Tmax (h) 4.2 ± 0.5 3.3 ± 0.3 
T1/2 (h) 5.4 ± 0.4 7.3 ± 0.9 
Cmax (µg/mL) 9.6 ± 0.3 9.2 ± 0.3 
AUC0-24 (µg·h/mL) 139 ± 5 129 ± 9  
AUC0-48h (µg·h/mL) 159 ± 8 156 ± 17 
AUC0-∞ (µg·h/mL) 159 ± 8 158 ± 18 
















Table 6:  Comparison of mean (± S.E.) pharmacokinetic parameters in yellowtail 
kingfish after oral administration of pure PZQ (control) or HCO-SLN chi3 (50 
mg PZQ per kg) coated to feed pellets with gelatine. No significant differences 
in any parameters between treatments (P > 0.05, with the Bonferroni).  
      
PK parameter 
Control HCO-SLNchi3 
(n = 10) (n = 10) 
Tmax (h) 4.5 ± 0.5 3.3 ± 0.3 
T1/2 (h) 11.4 ± 2.1 7.1 ± 1.0 
Cmax (µg/ml) 9.3 ± 0.7 11.6 ± 0.5 
AUC0-24 (µg·h/ml 133 ± 7 129 ± 9 
AUC0-48h (µg·h/ml) 158 ± 8 155 ± 16 
AUC0-∞ (µg·h/ml) 158 ± 8 156 ± 16 













Table 7: Palatability parameters measured in yellowtail kingfish fed various diets containing PZQ. There was a significant difference 
between treatments for all parameters in both trials (P < 0.05, with the Bonferroni). Values within the same row with different 
superscripts are significantly different (P<0.05) 
            
  Control Control gelatin HCO-SLN HCO-SLNchi3 Pure PZQ 
Trial 1           
% of total ration consumed
1
 100 ± 0%a 100 ± 0%a 41 ± 10%b - 56 ± 9%b 
% of the number of rations consumed within 3 minutes
2 100 ± 0%a 100 ± 0%a 0 ± 0b - 13 ± 13%b 
Average time taken to consume ration (seconds)
3 15 ± 1a 15 ± 1a na - 84 ± 12b 
            
Trial 2           
% of total ration consumed
1
 100 ± 0%a 100 ± 0%a - 34 ± 6%b 36 ± 4%b 
% of the number of rations consumed within 3 minutes
2 100 ± 0%a 100 ± 0%a - 3 ± 3%b 3 ± 3%b 
Average time taken to consume ration
3 17 ± 1a 19 ± 1a - 170* 28* 
            
1
 total ration = daily ration x 5 days           
2
 Number of rations = 10 (2 per day x 5 days)           
3
 Only for those rations which were consumed in <3 minutes           













Table 8: Comparison of studies testing bioavailability of PZQ in SLN in various animals 
                    




Dose AUC 0-∞ AUC0-24 Cmax Tmax T1/2 
                    
Xie et al (2010) Pure PZQ Mouse oral in solution 30 4 nd 1.1 0.2 4.7 
  HCO-SLN Mouse oral in solution 30 61 nd 1.1 0.4 20.1 
  Pure PZQ Mouse sub-cutaneous 30 6 nd 4.5 0.3 2.3 
  HCO-SLN Mouse sub-cutaneous 30 102 nd 1.4 0.3 29.6 
  Pure PZQ Mouse intramuscular 30 10 nd 5.4 0.2 4.3 
  HCO-SLN Mouse intramuscular 30 26 nd 2.7 0.3 11.7 
                    
                    
Xie et al (2011) Pure PZQ  Dog sub-cutaneous 5 1 nd 0.05 1.4 34.5 
  HCO-SLN Dog sub-cutaneous 5 6 nd 0.1 1.9 189.6 
                    
Yang et al (2009) ATO-SLN  Rat oral 60 12 nd 2.6 4.0 1.2 
  Pure PZQ  Rat oral 60 3 nd 2.1 0.3 1.8 
                    
Tubbs & Tingle 
(2006) Pure PZQ   YTK oral with food 40 nd 101 10.6 6.0 7.9 
    YTK oral in solution 40 nd 90 12.7 1.0 6.6 
    YTK IV 40 nd 178 20.3 0.5 8.6 
                    
Current Study HCO-SLN (powder)
1
 YTK oral with food 50 113 92 5.3 6.0 7.1 
  Pure PZQ (powder)
1
 YTK oral with food 50 133 106 6.9 6.0 7.6 
  HCO-SLN (gelatin)
2











  Pure PZQ (gelatin)
2





 YTK oral with food 50 156 129 11.6 3.3 7.1 
  Pure PZQ (gelatin)
3
 YTK oral with food 50 158 133 9.3 4.5 11.4 
                    
Trial 1; n = 2                   
Trial 2; n = 10                   
Trial 3; n = 10                   
















Figure 1: Dose normalized plasma PZQ concentrations (µg/mL) of large yellowtail kingfish following 
oral administration of PZQ formulations with powdered feed at 50 mg PZQ/kg. N = 3.  
Figure 2: Dose normalized plasma PZQ concentrations (µg/mL) of 305 gram yellowtail kingfish (n=10) 
following oral administration of PZQ formulations applied to feed with gelatine at 50 mg 
PZQ/kg.  
Figure 3:  Dose normalized plasma PZQ concentrations (µg/mL) of ca. 300 gram yellowtail kingfish 
(n=10) following oral administration of PZQ formulations applied to feed with gelatine at 50 


















 Solid lipid nanoparticles loaded with praziquantel were found to have the same 
bioavailability as pure praziquantel when intubated into yellowtail kingfish, regardless 
of whether the nanoparticles were coated with chitosan.  
 
 Palatability of diets containing these nanoparticles was equal to those containing the 
same quantity of pure praziquantel.  
 
 The results suggest that the lack of Peyer’s patches in fish may be responsible for the 
lack of bioavailability improvement by preventing uptake into the lymphatic system.  
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